Please assess the completion status of the following clinical trial:

Trial Title: Study of Leptin for the Treatment of Hypothalamic Amenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for HA subjects~* Hypothalamic amenorrhea of at least 6 months duration with low or normal LH and FSH, e.g. due to strenuous exercise (running \>20 miles per week or equivalent) or low weight~* Can be secondary HA OR primary HA with some pubertal development and normal screening labs~* Age 18-35 years old~* Body weight within +/- 15% of ideal body weight and stable for 6 months (no change \> 5 lbs)~* Baseline leptin \<5 ng/mL (except for the Cognitive Sub-Study Baseline visit where baseline leptin will be greater than 5ng/mL)~Inclusion criteria for eumenorrheic controls for Reward Sub-study~* Normal menstrual cycles (between 25 and 35 days)~* Age 18-35~* Body weight within +/- 15% of ideal body weight and stable 6 months (no change \> 5 lbs)~* Baseline leptin \>5 ng/mL~Exclusion criteria:~* We will exclude subjects with:~* Significant medical history that may affect the concentrations of the hormones to studied or ability to participate in the study~* renal or hepatic disease (creatinine \> 1.4, AST/ALT \> 2x upper limit of normal)~* diagnosed diabetes mellitus~* myocardial ischemia~* malignancy (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix)~* malabsorption~* alcoholism, drug abuse, or smoking~* active eating disorder~* depression or other psychiatric disease~* anemia (Hb10 gm/dL on 2 occasions)~* Conditions that are contraindicated for oral contraceptive use:~* Thrombophlebitis or thromboembolic disorders~* A past history of deep vein thrombophlebitis or thromboembolic disorders~* Cerebral vascular or coronary artery disease~* Known or suspected carcinoma of the breast~* Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia~* Undiagnosed abnormal genital bleeding~* Hepatic adenomas or carcinomas~* Cholestatic jaundice of pregnancy or jaundice with prior OCP use~* Other endocrine causes of amenorrhea, e.g.~* hyperprolactinemia~* hypothyroidism or hyperthyroidism~* Cushing's syndrome~* congenital adrenal hyperplasia (elevated 17 OH progesterone)~* polycystic ovarian syndrome (elevated androgens or LH/FSH ratio \>1.5)~* primary ovarian failure (elevated FSH)~* On medications known to affect the hormones to be measured such as~* glucocorticoids~* anti seizure medications~* thyroid hormones~* estrogen (must be off at least 3 months prior to participating in the study)~* A known history of anaphylaxis or anaphylactoid-like reactions, or a known hypersensitivity to E. Coli derived proteins~* Breast feeding, pregnant, or wanting to become pregnant during the next 6 months.~* We will screen for these conditions through a detailed history and systems review, physical examination, laboratory evaluation (as described above in Screening Methods), and EKG.~* In the Reward Sub-study subjects will be asked to fill out a standard BIDMC MRI safety screening form prior to entering the magnet.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- r-metHuLeptin (Type: EXPERIMENTAL): r-metHuLeptin administered subcutaneously.
- Oral Contraceptive Pills (OCPs) (Type: PLACEBO_COMPARATOR): PLACEBO

Based on this trial design, predict the completion outcome and termination type (if applicable).